Why CD4+ T cells matter in adoptive cell therapy for solid cancers
Authors:
- S. JegatheesonSJS. Jegatheeson
- C. SchefflerCSC. Scheffler
- M. De BondtMBM. De Bondt
- P.K. DarcyPDP.K. Darcy
- P.J. NeesonPNP.J. Neeson
Open Access
- 22 September 2026
- journal article
- Published by Elsevier in Immuno-Oncology and Technology
- Vol. 32
Abstract
No abstract availableFunding Information
- National Health and Medical Research Council
This publication has 78 references indexed in Scilit:
- Large B cell lymphoma microenvironment archetype profilesCancer Cell, 2025
- BCL6 overexpression in CD4+ T cells induces Tfh-like transdifferentiation and enhances antitumor efficiency of CAR-T therapy in pancreatic cancerBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2024
- Inosine induces stemness features in CAR-T cells and enhances potencyCancer Cell, 2024
- T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variantsCell, 2023
- Adoptive cell therapy with tumor-specific Th9 cells induces viral mimicry to eliminate antigen-loss-variant tumor cellsCancer Cell, 2021
- Multi-phenotype CRISPR-Cas9 Screen Identifies p38 Kinase as a Target for Adoptive ImmunotherapiesCancer Cell, 2020
- CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functionsCancer Immunology, Immunotherapy, 2018
- CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cellsFrontiers of Medicine, 2017
- Tumor‐specific CD4+T cells maintain effector and memory tumor‐specific CD8+T cellsEuropean Journal of Immunology, 2013
- Killing of myeloid APCs via HLA class I, CD2 and CD226 defines a novel mechanism of suppression by human Tr1 cellsEuropean Journal of Immunology, 2011